These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24374613)

  • 21. Autoimmunity in Chagas' disease. Identification of cardiac myosin-B13 Trypanosoma cruzi protein crossreactive T cell clones in heart lesions of a chronic Chagas' cardiomyopathy patient.
    Cunha-Neto E; Coelho V; Guilherme L; Fiorelli A; Stolf N; Kalil J
    J Clin Invest; 1996 Oct; 98(8):1709-12. PubMed ID: 8878420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy.
    Pereira IR; Vilar-Pereira G; Marques V; da Silva AA; Caetano B; Moreira OC; Machado AV; Bruna-Romero O; Rodrigues MM; Gazzinelli RT; Lannes-Vieira J
    PLoS Pathog; 2015 Jan; 11(1):e1004594. PubMed ID: 25617628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased levels of IgA antibodies against CRA and FRA recombinant antigens of Trypanosoma cruzi differentiate digestive forms of Chagas disease.
    Vasconcelos RH; Amaral FN; Cavalcanti MG; Silva ED; Ferreira AG; Morais CN; Gomes YM
    Hum Immunol; 2010 Oct; 71(10):964-7. PubMed ID: 20659514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chagas' disease: polyspecificity of antibodies against Trypanosoma cruzi acidic antigens.
    Ordoñez P; Gea S; Iosa D; Vottero-Cima E
    Acta Trop; 1995 May; 59(2):93-103. PubMed ID: 7676911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trypanosoma cruzi: cross-reactive anti-heart autoantibodies produced during infection in mice.
    McCormick TS; Rowland EC
    Exp Parasitol; 1989 Nov; 69(4):393-401. PubMed ID: 2509236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease.
    Barry MA; Wang Q; Jones KM; Heffernan MJ; Buhaya MH; Beaumier CM; Keegan BP; Zhan B; Dumonteil E; Bottazzi ME; Hotez PJ
    Hum Vaccin Immunother; 2016 Apr; 12(4):976-87. PubMed ID: 26890466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IgG subclass reactivity to Trypanosoma cruzi in chronic chagasic patients.
    Hernández-Becerril N; Nava A; Reyes PA; Monteón VM
    Arch Cardiol Mex; 2001; 71(3):199-205. PubMed ID: 11665655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice.
    Bhatia V; Garg NJ
    Clin Vaccine Immunol; 2008 Aug; 15(8):1158-64. PubMed ID: 18550728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine.
    Bivona AE; Sánchez Alberti A; Matos MN; Cerny N; Cardoso AC; Morales C; González G; Cazorla SI; Malchiodi EL
    PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006384. PubMed ID: 29601585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Humoral immune response against P2β from Trypanosoma cruzi in persons with chronic Chagas disease: its relationship with treatment against parasites and myocardial damage.
    Fabbro DL; Olivera V; Bizai ML; Denner S; Diez C; Marcipar I; Streiger M; Arias E; del Barco M; Mendicino D; Bottasso O
    Am J Trop Med Hyg; 2011 Apr; 84(4):575-80. PubMed ID: 21460013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EVI antibodies in patients with Chagas' disease: relationship with anti-Trypanosoma cruzi immunoglobulins and effects of specific treatment.
    Brener Z; Ramirez LE; Krettli AU; Cançado JR
    Mem Inst Oswaldo Cruz; 1983; 78(4):437-42. PubMed ID: 6443630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Origin and significance of anti-heart and anti-skeletal muscle autoantibodies in Chagas' disease.
    Laguens RP; Cabeza Meckert P; Chambo J
    Res Immunol; 1991 Feb; 142(2):160-3. PubMed ID: 1714090
    [No Abstract]   [Full Text] [Related]  

  • 33. Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients.
    Pérez-Antón E; Egui A; Thomas MC; Puerta CJ; González JM; Cuéllar A; Segovia M; López MC
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006480. PubMed ID: 29750791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-Trypanosoma cruzi immunoglobulin G1 can be a useful tool for diagnosis and prognosis of human Chagas' disease.
    Cordeiro FD; Martins-Filho OA; Da Costa Rocha MO; Adad SJ; Corrêa-Oliveira R; Romanha AJ
    Clin Diagn Lab Immunol; 2001 Jan; 8(1):112-8. PubMed ID: 11139203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cloning and expression of Trypanosoma cruzi ribosomal protein P0 and epitope analysis of anti-P0 autoantibodies in Chagas' disease patients.
    Skeiky YA; Benson DR; Parsons M; Elkon KB; Reed SG
    J Exp Med; 1992 Jul; 176(1):201-11. PubMed ID: 1377223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunoglobulin M antibodies against CRA and FRA recombinant antigens of Trypanosoma cruzi in chronic chagasic patients.
    Vasconcelos RH; Azevedo EA; Cavalcanti MG; Silva ED; Ferreira AG; Morais CN; Gomes YM
    Hum Immunol; 2011 May; 72(5):402-5. PubMed ID: 21371515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experimental Chagas disease. Innate immune response in Balb/c mice previously vaccinated with Trypanosoma rangeli. I. The macrophage shows immunological memory: Reality or fiction?
    Basso B; Marini V
    Immunobiology; 2014 Apr; 219(4):275-84. PubMed ID: 24321621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-Trypanosoma cruzi antibody isotype profiles in patients with different clinical manifestations of Chagas' disease.
    Morgan J; Dias JC; Gontijo ED; Bahia-Oliveira L; Correa-Oliveira R; Colley DG; Powell MR
    Am J Trop Med Hyg; 1996 Oct; 55(4):355-9. PubMed ID: 8916788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The beta1 adrenergic effects of antibodies against the C-terminal end of the ribosomal P2beta protein of Trypanosoma cruzi associate with a specific pattern of epitope recognition.
    Lopez Bergami P; Gómez KA; Levy GV; Grippo V; Baldi A; Levin MJ
    Clin Exp Immunol; 2005 Oct; 142(1):140-7. PubMed ID: 16178868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human recombinant antibodies against Trypanosoma cruzi ribosomal P2β protein.
    Grippo V; Niborski LL; Gomez KA; Levin MJ
    Parasitology; 2011 May; 138(6):736-47. PubMed ID: 21414241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.